Hormonal contraceptives (oral, parenteral, vaginal ring, or transdermal) that started at least  months prior to study drug administration
Double-barrier method (condom plus diaphragm or cervical cup with spermicidal contraceptive sponge, jellies, or cream)
A partner who is surgically sterile or postmenopausal (for at least  year) or who is taking hormonal contraceptives (oral, parenteral, vaginal ring, or transdermal) for at least  months prior to study drug administration
Double-barrier method (condom plus diaphragm or cervical cup with spermicidal, contraceptive sponge, jellies, or cream)
Women of childbearing potential (WOCP) must be willing to use two effective methods of birth control such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence for the course of the study until  days after the last dose of study drug. NOTE: Women are considered to be of childbearing potential unless they are postmenopausal (? years of age and has not had menses for greater than  consecutive months), surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or not heterosexually active for the duration of the study and at least  days after the last dose of study drug.
Women of child-bearing potential and men must agree to use adequate contraception (one of the following listed below) prior to the study entry, for the duration of study participation and up to  months following completion of therapy; women of child-bearing potential must have a negative pregnancy test within  days prior to initiation of treatment and post-menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential\r\n* Acceptable contraception\r\n** Total abstinence from sexual intercourse (minimum one complete menstrual cycle)\r\n** Vasectomized male subjects or vasectomized partner of female subjects\r\n** Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream)\r\n** Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for  months following completion of therapy
Women of child-bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry, for the duration of study participation, and for  months for women and  months for men following the date of the last dose of AZD and/or navitoclax:\r\n* Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration)\r\n* Vasectomized male subject or vasectomized partner of female subjects\r\n* Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) for at least  months prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for  months after study completion\r\n* Intrauterine device (IUD)\r\n* Double-barrier method: male condom plus diaphragm or vaginal cap with spermicide (contraceptive sponge, jellies or creams)\r\n* Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and  months following completion of therapy
If a WOCP, agree to use during the study and for at least one month after the last dose of study drug a medically acceptable method of birth control [such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence.];
During screening, while taking study drug, and until  days after taking the final dose of study drug, women of childbearing potential (WOCBP) must practice one of the following methods of birth control\r\n* Use double-barrier contraception method defined as male use of a condom and female use of a barrier method (e.g., contraceptive sponge, spermicidal jelly or cream, diaphragm [always use with spermicidal jelly/cream])\r\n* Use of hormonal contraceptives (oral, parenteral, vaginal, or transdermal) for at least  months before the first study drug administration\r\n* Use of an intrauterine device\r\n* Have a male partner who has had a vasectomy (at least  months prior to study enrollment)\r\n* Or must abstain from sexual intercourse completely
During screening, while taking study drug, and until  days after taking the final dose of study drug, men who are sexually active with WOCBP must practice one of the following methods of birth control:\r\n* Have had a vasectomy (at least  months prior to study enrollment)\r\n* Use double-barrier contraception method defined as male use of a condom and female use of a barrier method (e.g., contraceptive sponge, spermicidal jelly or cream, diaphragm [always use with spermicidal jelly/cream])\r\n* Partner use of an intrauterine device\r\n* Partner use of hormonal contraceptives (oral, parenteral, vaginal, or transdermal) for at least  months before the first study drug administration\r\n* Or must abstain from sexual intercourse completely
Women of child-bearing potential and men must agree to use adequate contraception (one of the following listed below) prior to the study entry, for the duration of study participation and up to  months following completion of therapy; women of child-bearing potential must have a negative pregnancy test within  days prior to initiation of treatment and/or post menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential\r\n* Total abstinence from sexual intercourse (minimum one complete menstrual cycle)\r\n* Vasectomized male subjects or vasectomized partner of female subjects \r\n* Intrauterine device \r\n* Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream)\r\n* Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for  months following completion of therapy
Women of child-bearing potential and men with a female partner of child bearing potential must agree to use adequate contraception using one of the methods listed below prior to study entry, for the duration of study participation, and up to  months following completion of therapy:\r\n* Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration)\r\n* Vasectomized male subject or vasectomized partner of female subjects\r\n* Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) for at least  months prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for  month after study completion\r\n* Intrauterine device (IUD)\r\n* Double-barrier method: male condom plus diaphragm or vaginal cap with spermicide (contraceptive sponge, jellies or creams)\r\n* Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for  months following completion of therapy
Women of childbearing potential must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and up to  months following completion of protocol therapy\r\n* Total abstinence from sexual intercourse (minimum one complete menstrual cycle)\r\n* A vasectomized partner\r\n* Hormonal contraceptives (oral, parenteral or transdermal) for at least  months prior to study drug administration\r\n* Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream)
Any of the following: \r\n* Pregnant women\r\n* Nursing women \r\n* Women of childbearing potential who are unwilling to employ adequate contraception; NOTE: should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of child-bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry, for the duration of study participation, and up to  days following completion of therapy:\r\n** Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration) \r\n** Vasectomized male subject or vasectomized partner of female subjects\r\n** Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) for at least  months prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for  month after study completion\r\n** Intrauterine device (IUD)\r\n** Double-barrier method: male condom plus diaphragm or vaginal cap with spermicide (contraceptive sponge, jellies or creams)\r\n** Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for  days following completion of therapy
Women of child-bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry, for the duration of study participation, and for  months for women and  months for men following the date of the last dose of AZD and/or necitumumab:\r\n* Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration)\r\n* Vasectomized male subject or vasectomized partner of female subjects\r\n* Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for  months after study completion\r\n* Intrauterine device (IUD)\r\n* Double-barrier method: male condom plus diaphragm or vaginal cap with spermicide (contraceptive sponge, jellies or creams)\r\n* Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for  months following completion of therapy
Double barrier method (condoms, sponge, diaphragm or vaginal ring with spermicidal jellies or cream
Women of childbearing potential (WOCP) must not be pregnant (confirmed by a negative pregnancy test, with a serum beta-HCG with a sensitivity of  mIU/ml within  days of study treatment) or breast-feeding. In addition, a medically acceptable method of birth control must be used such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence during the study and at least one month after the last dose of study drug. Women who are postmenopausal for at least  year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP.
Non-vasectomized male patients must practice at least one of the following methods of birth control throughout the duration of study participation and for at least  months after study treatment:\r\n* A partner who is surgically sterile or postmenopausal (for at least  year) or who is taking hormonal contraceptives (oral, parenteral, vaginal ring, or transdermal) for at least  months prior to study drug administration\r\n* Total abstinence from sexual intercourse\r\n* Double-barrier method (condom, diaphragm or cervical cup with spermicidal, contraceptive sponge, jellies, or cream)
Women of childbearing potential (WOCP) must be willing to use two effective methods of birth control such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence for the course of the study until  days after the last dose of study drug.
If not postmenopausal or surgically sterile, study patients must be willing to practice at least one of the following methods of birth control for at least a menstrual cycle before and after study drug administration: () total abstinence from sexual intercourse with a male; () sexual intercourse with vasectomized male partner; () other acceptable forms of birth control (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicide or cream); () use of an intrauterine contraceptive device
Female patient of child-bearing potential or male patient with partner of child-bearing potential but unable or unwilling to use effective contraception (double barrier such as condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream; or hormonal method such as oral, parenteral or transdermal hormonal agents for at least three months prior to study drug administration)